Abstract:Introduction: Targeted biologic immunomodulatory therapies have had a major impact in rheumatoid arthritis (RA) treatment, including tumor necrosis factor (TNF)-α inhibition, B-cell depletion, interference in T-cell costimulation and interleukin (IL)-1 and IL-6 inhibition. Along with the recognition of the importance of early, aggressive disease-modifying antirheumatic drugs (DMARDs) grounded in the use of methotrexate, the introduction of biologic DMARDs (bDMARDs) has provided significantly improved outcomes in patients with RA with a goal of true remission, or at least a state of very low disease activity, now possible in many. There are a number of methods to inhibit cytokines, cellular receptors and pathways of signal transduction that have been used thus far and are in development. In some cases, the method of target inhibition and differences in molecular construct has impacted efficacy and/or safety; whereas, in other cases, similar safety and/or efficacy signals across compounds have demonstrated class- or target-related effects. As the development of targeted therapies moves forward, it is increasingly important to understand the role of the target both in RA disease pathogenesis and normal host defense and the mechanisms of target inhibition. Areas covered: This review covers the targets of therapy for biologic agents in rheumatic diseases, their molecular constructs and implications on efficacy and safety, with focus on approved treatments for RA. Expert opinion: Advances in molecular biology have provided a number of different ways to impact pathobiologically relevant pathways and targets in terms of the molecular construct of individual compounds. The use of these agents have provided important mechanistic insights into disease pathogenesis, and in some cases are associated with differences in efficacy and safety among agents even with the same downstream target. As bDMARDs identify promising mechanisms, oral agents that target or specifically regulate downstream pathways are made possible.

Experience and consensus on biological agents for treatment of rheumatoid arthritis

Expert Consensus on the Treat-to-target Strategy for Psoriasis with Biological Agents in China

Progress on the Clinical Application of Traditional Chinese Medicine in Treatment of Rheumatoid Arthritis

Therapy Development of B iological Agents in Inflammatory Arthritis

Expert consensus on clinical application of Wangbi Tablets in treating rheumatoid arthritis and knee osteoarthritis

Functional components from nature-derived drugs for the treatment of rheumatoid arthritis.

Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis

Rheumatoid arthritis: non-tumor necrosis factor targets

Adalimumab in the Treatment of Rheumatoid Arthritis

Research progress of plant medicine and Chinese herbal compounds in the treatment of rheumatoid arthritis combined with osteoporosis

Research progress on integrative Chinese and western medicine for rheumatoid arthritis

[Traditional Chinese medicine therapy for rheumatoid arthritis: a review].

[The standardized diagnosis and treatment of rheumatoid arthritis].

The role, targets and mechanisms of traditional Chinese medicine in regulating the balance of T helper type 17/regulatory Tcells in rheumatoid arthritis

Research progress in the treatment of rheumatoid arthritis

Therapeutic advances in rheumatoid arthritis

Research Progress of Biological Agents in the Treatment of Systemic Lupus Erythematosus

Progress of Biologics in Therapeutics of Rheumatoid Arthritis

Exploring the therapeutic potential of "Tianyu" medicine pair in rheumatoid arthritis: an integrated study combining LC-MS/MS, bioinformatics, network pharmacology, and experimental validation

The Therapeutic Potential of Targeted Nanoparticulate Systems to Treat Rheumatoid Arthritis

Trends of Treatment Development in Rheumatoid Arthritis: Promise, Progress, and Challenges